TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
نيوروكرين بيوساينسز
Neurocrine Biosciences, Inc. NBIX | 0.00 |
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:
NBIX) with a Buy and raises the price target from $200 to $220.
